Treating migraine before the pain starts: New research shows ubrogepant eases premonitory symptoms, offering hope for millions seeking earlier and more effective relief.
Study: Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial. Image Credit: GoodStudio / Shutterstock
The most recent exploratory analysis from the phase 3 PRODROME trial reveals that ubrogepant, a calcitonin gene-related peptide receptor antagonist, administered at the initial phase of a migraine attack, may ameliorate common premonitory symptoms, including fatigue, light and sound sensitivity, neck pain, and dizziness. A detailed report is published in the journal Nature Medicine.
Background
Migraine is a common neurological disorder characterized by…